Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)

Annals of Oncology : Official Journal of the European Society for Medical Oncology
Aristotelis BamiasRISC Investigators

Abstract

Cisplatin-based combination chemotherapy is the standard treatment of advanced urinary tract cancer (aUTC), but 50% of patients are ineligible for cisplatin according to recently published criteria. We used a multinational database to study patterns of chemotherapy utilization in patients with aUTC and determine their impact on survival. This was a retrospective study of patients with: UTC (bladder, renal pelvis, ureter or urethra); advanced disease (stages T4b and/or N+ and/or M+); urothelial, squamous or adenocarcinoma histology. Primary objective was overall survival (OS). Eligibility-for-cisplatin was defined by Eastern Cooperative Oncology Group performance status ≤ 1, creatinine clearance ≥ 60 ml/min, no hearing loss, no neuropathy and no heart failure. Cox regression multivariate analyses were used to establish independent associations of cisplatin versus noncisplatin-based chemotherapy on OS. 1794 patients treated between 2000 and 2013 at 29 centers were analyzed. Median follow-up was 29.1 months. About 1333 patients (74%) received first-line chemotherapy: the use of first-line chemotherapy was associated with longer OS: [hazard ratio (HR): 1.91, 95% confidence interval (CI): 1.67-2.20]. Type of first-line chemotherapy ...Continue Reading

References

Oct 3, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D F BajorinM G Boyle
May 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C N SternbergUNKNOWN European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group
Oct 26, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J BellmuntJ Baselga
Dec 11, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A BamiasUNKNOWN Hellenic Cooperative Oncology Group
May 11, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew D GalskyJoaquim Bellmunt
Feb 22, 2012·Clinical Genitourinary Cancer·Guru SonpavdeNicholas J Vogelzang
Aug 7, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J BellmuntUNKNOWN ESMO Guidelines Working Group
Sep 18, 2016·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Jorge D RamosUNKNOWN Retrospective International Study of Cancers of the Urothelium (RISC) Investigators

❮ Previous
Next ❯

Citations

Jun 27, 2018·PloS One·Sébastien Bontemps-GalloFrank C Gherardini
Feb 12, 2019·Current Treatment Options in Oncology·David J Einstein, Guru Sonpavde
Aug 28, 2020·Asia-Pacific Journal of Clinical Oncology·Darren Ming-Chun Poon
Jul 9, 2020·Cancer Management and Research·Christine FischerAxel Hegele
Jan 13, 2021·Nature Reviews. Urology·Di Maria JiangSrikala S Sridhar
Mar 13, 2021·Targeted Oncology·Enrique GrandeAndrea Necchi
Oct 28, 2019·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Karin HolmstenAnders Ullén

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.